Cell interventions for orthopaedic conditions: separate indication, product and outcome
Knee osteoarthritis, focal cartilage defects, tendon injuries and spine pain are not one indication, and injections marketed as regenerative medicine are not one product.
Start with a diagnosis and established care pathway. For osteoarthritis, record symptoms, function, imaging when clinically needed, exercise and weight-management support, medicines, prior injections and surgical opinion. A marketed cell procedure should not delay treatment with clearer evidence or assessment of red flags.
Identify the intervention precisely: bone-marrow aspirate concentrate, adipose preparation, culture-expanded MSC product, characterised chondrocytes, platelet product or another material. Record autologous or allogeneic status, manipulation, dose, route, imaging guidance, manufacturer and release tests. Results for a licensed chondrocyte product in a defined focal cartilage defect do not validate a different injection for general osteoarthritis.
Read evidence by exact product and indication. Prioritise randomised comparisons, validated pain and function scales, clinically meaningful thresholds, rescue treatment, structural outcomes, adverse events and sufficient follow-up. Small uncontrolled cohorts cannot establish cartilage regrowth or show that an injection prevents joint replacement.
Regulatory status must also match. Ask for the marketing-authorisation reference, authorised clinical-trial identifier or specific national legal basis for the product, site and proposed use. Facility licensing, a laboratory certificate, autologous sourcing or a registry entry does not by itself establish authorisation or efficacy.
NICE describes intra-articular stem-cell injections for osteoarthritis as experimental and a research question, while the FDA consumer information says regenerative medicine therapies are not approved for orthopaedic conditions in the United States. These statements prevent broad marketing claims from replacing product-level evidence.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.